IDH1 and glioblastoma: Interestingly, a recent observational prospective study describes how GBM patients with wild-type IDH1/2, with a Karnofsky Performance Score >80, treated with concomitant radio-chemotherapy and subsequent chemotherapy with TMZ—which presented non-local recurrence—have poorer overall survival than patients with local recurrence [77].